Association of HLA-DRB1*1501 tagging rs3135388 gene polymorphism with multiple sclerosis

Journal of Neuroimmunology

Volumn 255, Issue 1-2, 2013, Pages 92-96

  Benešová, Yvonne ^a   Vašků, Anna ^b   Štourač, Pavel ^a,b   Hladíková, Magdalena ^a   Fiala, Adam ^b   Bednařík, Josef ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

1501; Gene; HLA DRB1; Multiple sclerosis; Tagging polymorphism

Indexed keywords

HLA DRB1 ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC MARKER; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE;

ADULT; CASE-CONTROL STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; GENETIC ASSOCIATION STUDIES; HLA-DRB1 CHAINS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYMORPHISM, GENETIC; SEX FACTORS;

EID: 84872662299     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.10.014     Document Type: Article

References (38)

1. Alcina A., Abad-Grau Mdel M., Fedetz M., Izquierdo G., Lucas M., Fernández O., Ndagire D., Catalá-Rabasa A., Ruiz A., Gayán J., Delgado C., Arnal C., Matesanz F. Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations. PLoS One 2012, 7:e29819.
2. Ballerini C., Guerini F.R., Rombolà G., Rosati E., Massacesi L., Ferrante P., Caputo D., Talamanca L.F., Naldi P., Liguori M., Alizadeh M., Momigliano-Richiardi P., D'Alfonso S. HLA-multiple sclerosis association in continental Italy and correlation with disease prevalence in Europe. J. Neuroimmunol. 2004, 150:178-185.
3. Cordell H.J., Clayton D.G. Genetic association studies. Lancet 2005, 366:1121-1131.
4. Corse E., Gottschalk R.A., Allison J.P. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J. Immunol. 2011, 186:5039-5045.
5. Cox M.B., Ban M., Bowden N.A., Baker A., Scott R.J., Lechner-Scott J. Potential association of vitamin D receptor polymorphism Taq1 with multiple sclerosis. Mult. Scler. 2012, 18:16-22.
6. de Bakker P.I., McVean G., Sabeti P.C., Miretti M.M., Green T., Marchini J., Ke X., Monsuur A.J., Whittaker P., Delgado M., Morrison J., Richardson A., Walsh E.C., Gao X., Galver L., Hart J., Hafler D.A., Pericak-Vance M., Todd J.A., Daly M.J., Trowsdale J., Wijmenga C., Vyse T.J., Beck S., Murray S.S., Carrington M., Gregory S., Deloukas P., Rioux J.D. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat. Genet. 2006, 38:1166-1172.
7. De Jager P.L., Simon K.C., Munger K.L., Rioux J.D., Hafler D.A., Ascherio A. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008, 70:1113-1118.
8. Ebers G. Genetic factors in multiple sclerosis. MS Forum; Modern Management Workshop, Boston 1995.
9. Fernández O., Fernández V., Alonso A., Caballero A., Luque G., Bravo M., León A., Mayorga C., Leyva L., de Ramón E. DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain. J. Neurol. 2004, 251:440-444.
10. Goris A., Walton A., Ban M., Dubois B., Compston A., Sawcer S. A Taqman assay for high-throughput genotyping of the multiple sclerosis-associated HLA-DRB1*1501 allele. Tissue Antigens 2008, 72:401-403.
11. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., de Bakker P.I., Gabriel S.B., Mirel D.B., Ivinson A.J., Pericak-Vance M.A., Gregory S.G., Rioux J.D., McCauley J.L., Haines J.L., Barcellos L.F., Cree B., Oksenberg J.R., Hauser S.L. International Multiple Sclerosis Genetics Consortium, 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357:851-862.
12. Hartung H.P., Bar-Or A., Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS?. J. Neurol. 2004, 251:12-29.
13. Hensiek A.E., Sawcer S.J., Feakes R., Deans J., Mander A., Akesson E., Roxburgh R., Coraddu F., Smith S., Compston D.A. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2002, 72:184-187.
14. Kikuchi S., Fukazawa T., Niino M., Yabe I., Miyagishi R., Hamada T., Tashiro K. Estrogen receptor gene polymorphism and multiple sclerosis in Japanese patients: interaction with HLA-DRB1*1501 and disease modulation. J. Neuroimmunol. 2002, 128:77-81.
15. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983, 33:1444-1452.
16. Lang H.L., Jacobsen H., Ikemizu S., Andersson C., Harlos K., Madsen L., Hjorth P., Sondergaard L., Svejgaard A., Wucherpfennig K., Stuart D.I., Bell J.I., Jones E.Y., Fugger L. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 2002, 3:940-943.
17. Lincoln M.R., Montpetit A., Cader M.Z., Saarela J., Dyment D.A., Tiislar M., Ferretti V., Tienari P.J., Sadovnick A.D., Peltonen L., Ebers G.C., Hudson T.J. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat. Genet. 2005, 37:1108-1112.
18. Lossius A., Vartdal F., Holmøy T. Vitamin D sensitive EBNA-1 specific T cells in the cerebrospinal fluid of patients with multiple sclerosis. J. Neuroimmunol. 2011, 240-241:87-96.
19. Luomala M., Elovaara I., Ukkonen M., Koivula T., Lehtimäki T. The combination of HLA-DR1 and HLA-DR53 protects against MS. Neurology 2001, 56:383-385.
20. Masterman T., Ligers A., Olsson T., Andersson M., Olerup O., Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann. Neurol. 2000, 48:211-219.
21. Matiello M., Schaefer-Klein J., Brum D.G., Atkinson E.J., Kantarci O.H., Kantarci O.H., Weinshenker B.G. HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica. Mult. Scler. 2010, 16:981-984. NMO genetics collaborators.
22. Mattila K.M., Luomala M., Lehtimaki T., Laippala P., Koivula T., Elovaara I. Interaction between ESR1 and HLA-DR2 may contribute to the development of MS in women. Neurology 2001, 56:1246-1247.
23. McDonnell G.V., Mawhinney H., Graham C.A., Hawkins S.A., Middleton D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J. Neurol. Sci. 1999, 165:77-83.
24. Nicot A. Gender and sex hormones in multiple sclerosis pathology and therapy. Front. Biosci. 2009, 14:4477-4515.
25. Niller H.H., Wolf H., Ay E., Minarovits J. Epigenetic dysregulation of epstein-barr virus latency and development of autoimmune disease. Adv. Exp. Med. Biol. 2011, 711:82-102.
26. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
27. Prat E., Tomaru U., Sabater L., Park D.M., Granger R., Kruse N., Ohayon J.M., Bettinotti M.P., Martin R. HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J. Neuroimmunol. 2005, 167:108-119.
28. Ramagopalan S.V., Maugeri N.J., Handunnetthi L., Lincoln M.R., Orton S.M., Dyment D.A., Deluca G.C., Herrera B.M., Chao M.J., Sadovnick A.D., Ebers G.C., Knight J.C. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009, 5:e1000369.
29. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., le Page E., Edan G., McDonnell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., SØrensen P.S., Celius E.G., Lara N.T., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sá M., Salemi G., Savettieri G., Hillert J., Compston D.A. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005, 64:1144-1151.
30. Sadovnick A.D. Genetic background of multiple sclerosis. Autoimmun. Rev. 2012, 11:163-166.
31. Sawcer S., Hellenthal G., Pirinen M., Spencer C.C., Patsopoulos N.A., Moutsianas L., et al. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
32. Schmidt H., Williamson D., Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am. J. Epidemiol. 2007, 165:1097-1109.
33. Sombekke M.H., Lukas C., Crusius J.B., Tejedor D., Killestein J., Arteta D., Martínez A., Uitdehaag B.M., Knol D.L., Peña A.S., Geurts J.J., De Jager P.L., Barkhof F., Vrenken H., Polman C.H. HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch. Neurol. 2009, 2009(66):1531-1536.
34. Sundström P., Nyström M., Ruuth K., Lundgren E. Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis. J. Neuroimmunol. 2009, 30(215):102-107.
35. Vasconcelos C.C., Fernández O., Leyva L., Thuler L.C., Alvarenga R.M. Does the DRB1*1501 allele confer more severe and faster progression in primary progressive multiple sclerosis patients? HLA in primary progressive multiple sclerosis. J. Neuroimmunol. 2009, 29(214):101-103.
36. Weatherby S.J., Thomson W., Pepper L., Donn R., Worthington J., Mann C.L., Davies M.B., Fryer A.A., Boggild M.D., Young C.A., Jones P.W., Strange R.C., Ollier W.E., Hawkins C.P. HLA-DRB1 and disease outcome in multiple sclerosis. J. Neurol. 2001, 248:304-310.
37. Weinshenker B.G., Santrach P., Bissonet A.S., McDonnell S.K., Schaid D., Moore S.B., Rodriguez M. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 1998, 51:742-747.
38. Živkovič M., Stankovič A., Dinčič E., Popovič M., Popovič S., Raicević R., Alavantič D. The tag SNP for HLA-DRB1*1501, rs3135388, is significantly associated with multiple sclerosis susceptibility: cost-effective high-throughput detection by real-time PCR. Clin. Chim. Acta 2009, 406:27-30.